The global market for Neuromyelitis Optica Drug was estimated to be worth US$ 47 million in 2023 and is forecast to a readjusted size of US$ 58 million by 2030 with a CAGR of 3.0% during the forecast period 2024-2030.

Neuromyelitis Optica Drug Market

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.

The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neuromyelitis Optica Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Market Segmentation

Scope of Neuromyelitis Optica Drug Market Report

Report Metric	Details
Report Name	Neuromyelitis Optica Drug Market
Forecasted market size in 2030	US$ 58 million
CAGR	3.0%
Forecasted years	2024 - 2030
Segment by Type	Glucocorticoids Immunotherapies Others
Segment by Application	Acute Attack Remission Prophylactic Treatment
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Neuromyelitis Optica Drug in global and regional level.
Chapter 3: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Drug revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion

FAQ for this report

What is the Neuromyelitis Optica Drug Market size in 2030?

Ans: The Neuromyelitis Optica Drug Market size in 2030 will be US$ 58 million.

What is the Neuromyelitis Optica Drug Market share by region?

Ans: Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

What is the market share of major companies in Neuromyelitis Optica Drug Market?

Ans: Top 3 companies occupied about 35% market share.

Who are the main players in the Neuromyelitis Optica Drug Market report?

Ans: The main players in the Neuromyelitis Optica Drug Market are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP

What are the Application segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Applications covered in the Neuromyelitis Optica Drug Market report are Acute Attack, Remission Prophylactic Treatment

What are the Type segmentation covered in the Neuromyelitis Optica Drug Market report?

Ans: The Types covered in the Neuromyelitis Optica Drug Market report are Glucocorticoids, Immunotherapies, Others

1 Study Coverage

1.1 Neuromyelitis Optica Drug Product Introduction

1.2 Market by Type

1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (2019 VS 2023 VS 2030)

1.2.2 Glucocorticoids

1.2.3 Immunotherapies

1.2.4 Others

1.3 Market by Application

1.3.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Application (2019 VS 2023 VS 2030)

1.3.2 Acute Attack

1.3.3 Remission Prophylactic Treatment

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Neuromyelitis Optica Drug Market Size Estimates and Forecasts

2.2 Neuromyelitis Optica Drug Market Size by Region: 2023 Versus 2030

2.2.1 Global Neuromyelitis Optica Drug Revenue by Region: 2019-2024

2.2.2 Global Neuromyelitis Optica Drug Revenue Forecast by Region (2025-2030)

2.2.3 Global Neuromyelitis Optica Drug Revenue Market Share by Region (2019-2030)

3 Global Neuromyelitis Optica Drug by Company

3.1 Global Neuromyelitis Optica Drug Revenue by Company (2019-2024)

3.2 Global Neuromyelitis Optica Drug Revenue Share by Company (2019-2024)

3.3 Competitive Landscape

3.3.1 Key Neuromyelitis Optica Drug Companies around the World: Ranking by Revenue

3.3.2 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI) & (2019-2024)

3.3.3 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.4 Global Neuromyelitis Optica Drug Companies Headquarters & Product Type

3.4.1 Neuromyelitis Optica Drug Companies Headquarters

3.4.2 Global Neuromyelitis Optica Drug Companies Product & Service

3.4.3 Date of International Companies Enter into Neuromyelitis Optica Drug Market

3.5 Global Neuromyelitis Optica Drug Mergers & Acquisitions, Expansion Plans

4 Company Profiles

4.1 Pfizer

4.1.1 Pfizer Company Information

4.1.2 Pfizer Description, Business Overview

4.1.3 Pfizer Neuromyelitis Optica Drug Products Offered

4.1.4 Pfizer Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.1.5 Pfizer Neuromyelitis Optica Drug Revenue by Product in 2023

4.1.6 Pfizer Neuromyelitis Optica Drug Revenue by Application in 2023

4.1.7 Pfizer Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.1.8 Pfizer Recent Developments

4.2 Fresenius

4.2.1 Fresenius Company Information

4.2.2 Fresenius Description, Business Overview

4.2.3 Fresenius Neuromyelitis Optica Drug Products Offered

4.2.4 Fresenius Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.2.5 Fresenius Neuromyelitis Optica Drug Revenue by Product in 2023

4.2.6 Fresenius Neuromyelitis Optica Drug Revenue by Application in 2023

4.2.7 Fresenius Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.2.8 Fresenius Recent Developments

4.3 Teva

4.3.1 Teva Company Information

4.3.2 Teva Description, Business Overview

4.3.3 Teva Neuromyelitis Optica Drug Products Offered

4.3.4 Teva Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.3.5 Teva Neuromyelitis Optica Drug Revenue by Product in 2023

4.3.6 Teva Neuromyelitis Optica Drug Revenue by Application in 2023

4.3.7 Teva Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.3.8 Teva Recent Developments

4.4 Sandoz

4.4.1 Sandoz Company Information

4.4.2 Sandoz Description, Business Overview

4.4.3 Sandoz Neuromyelitis Optica Drug Products Offered

4.4.4 Sandoz Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.4.5 Sandoz Neuromyelitis Optica Drug Revenue by Product in 2023

4.4.6 Sandoz Neuromyelitis Optica Drug Revenue by Application in 2023

4.4.7 Sandoz Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.4.8 Sandoz Recent Developments

4.5 Intas

4.5.1 Intas Company Information

4.5.2 Intas Description, Business Overview

4.5.3 Intas Neuromyelitis Optica Drug Products Offered

4.5.4 Intas Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.5.5 Intas Neuromyelitis Optica Drug Revenue by Product in 2023

4.5.6 Intas Neuromyelitis Optica Drug Revenue by Application in 2023

4.5.7 Intas Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.5.8 Intas Recent Developments

4.6 Gyjtrs

4.6.1 Gyjtrs Company Information

4.6.2 Gyjtrs Description, Business Overview

4.6.3 Gyjtrs Neuromyelitis Optica Drug Products Offered

4.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.6.5 Gyjtrs Neuromyelitis Optica Drug Revenue by Product in 2023

4.6.6 Gyjtrs Neuromyelitis Optica Drug Revenue by Application in 2023

4.6.7 Gyjtrs Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.6.8 Gyjtrs Recent Development

4.7 NANG KUANG

4.7.1 NANG KUANG Company Information

4.7.2 NANG KUANG Description, Business Overview

4.7.3 NANG KUANG Neuromyelitis Optica Drug Products Offered

4.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.7.5 NANG KUANG Neuromyelitis Optica Drug Revenue by Product in 2023

4.7.6 NANG KUANG Neuromyelitis Optica Drug Revenue by Application in 2023

4.7.7 NANG KUANG Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.7.8 NANG KUANG Recent Development

4.8 Tianjin Kingyork

4.8.1 Tianjin Kingyork Company Information

4.8.2 Tianjin Kingyork Description, Business Overview

4.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Products Offered

4.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.8.5 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Product in 2023

4.8.6 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Application in 2023

4.8.7 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.8.8 Tianjin Kingyork Recent Development

4.9 Baxter

4.9.1 Baxter Company Information

4.9.2 Baxter Description, Business Overview

4.9.3 Baxter Neuromyelitis Optica Drug Products Offered

4.9.4 Baxter Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.9.5 Baxter Neuromyelitis Optica Drug Revenue by Product in 2023

4.9.6 Baxter Neuromyelitis Optica Drug Revenue by Application in 2023

4.9.7 Baxter Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.9.8 Baxter Recent Development

4.10 CSL

4.10.1 CSL Company Information

4.10.2 CSL Description, Business Overview

4.10.3 CSL Neuromyelitis Optica Drug Products Offered

4.10.4 CSL Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.10.5 CSL Neuromyelitis Optica Drug Revenue by Product in 2023

4.10.6 CSL Neuromyelitis Optica Drug Revenue by Application in 2023

4.10.7 CSL Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.10.8 CSL Recent Development

4.11 Grifols

4.11.1 Grifols Company Information

4.11.2 Grifols Description, Business Overview

4.11.3 Grifols Neuromyelitis Optica Drug Products Offered

4.11.4 Grifols Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.11.5 Grifols Neuromyelitis Optica Drug Revenue by Product in 2023

4.11.6 Grifols Neuromyelitis Optica Drug Revenue by Application in 2023

4.11.7 Grifols Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.11.8 Grifols Recent Development

4.12 Octapharma

4.12.1 Octapharma Company Information

4.12.2 Octapharma Description, Business Overview

4.12.3 Octapharma Neuromyelitis Optica Drug Products Offered

4.12.4 Octapharma Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.12.5 Octapharma Neuromyelitis Optica Drug Revenue by Product in 2023

4.12.6 Octapharma Neuromyelitis Optica Drug Revenue by Application in 2023

4.12.7 Octapharma Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.12.8 Octapharma Recent Development

4.13 CBOP

4.13.1 CBOP Company Information

4.13.2 CBOP Description, Business Overview

4.13.3 CBOP Neuromyelitis Optica Drug Products Offered

4.13.4 CBOP Neuromyelitis Optica Drug Revenue and Gross Margin (2019-2024)

4.13.5 CBOP Neuromyelitis Optica Drug Revenue by Product in 2023

4.13.6 CBOP Neuromyelitis Optica Drug Revenue by Application in 2023

4.13.7 CBOP Neuromyelitis Optica Drug Revenue by Geographic Area in 2023

4.13.8 CBOP Recent Development

5 Breakdown Data by Type

5.1 Global Neuromyelitis Optica Drug Revenue by Type (2019-2024)

5.2 Global Neuromyelitis Optica Drug Revenue Forecast by Type (2025-2030)

5.3 Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2030)

6 Breakdown Data by Application

6.1 Global Neuromyelitis Optica Drug Revenue by Application (2019-2024)

6.2 Global Neuromyelitis Optica Drug Revenue Forecast by Application (2025-2030)

6.3 Neuromyelitis Optica Drug Revenue Market Share by Application (2019-2030)

7 North America

7.1 North America Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030

7.2 North America Neuromyelitis Optica Drug Market Facts & Figures by Country (2019-2030)

7.3 North America Neuromyelitis Optica Drug Revenue by Type (2019-2024)

7.4 North America Neuromyelitis Optica Drug Revenue by Application (2019-2024)

8 Asia-Pacific

8.1 Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030

8.2 Asia-Pacific Neuromyelitis Optica Drug Market Facts & Figures by Region (2019-2030)

8.3 Asia-Pacific Neuromyelitis Optica Drug Revenue by Type (2019-2024)

8.4 Asia-Pacific Neuromyelitis Optica Drug Revenue by Application (2019-2024)

9 Europe

9.1 Europe Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030

9.2 Europe Neuromyelitis Optica Drug Market Facts & Figures by Country (2019-2030)

9.3 Europe Neuromyelitis Optica Drug Revenue by Type (2019-2024)

9.4 Europe Neuromyelitis Optica Drug Revenue by Application (2019-2024)

10 Latin America

10.1 Latin America Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030

10.2 Latin America Neuromyelitis Optica Drug Market Facts & Figures by Country (2019-2030)

10.3 Latin America Neuromyelitis Optica Drug Revenue by Type (2019-2024)

10.4 Latin America Neuromyelitis Optica Drug Revenue by Application (2019-2024)

11 Middle East and Africa

11.1 Middle East and Africa Neuromyelitis Optica Drug Market Size YoY Growth 2019-2030

11.2 Middle East and Africa Neuromyelitis Optica Drug Market Facts & Figures by Country (2019-2030)

11.3 Middle East and Africa Neuromyelitis Optica Drug Revenue by Type (2019-2024)

11.4 Middle East and Africa Neuromyelitis Optica Drug Revenue by Application (2019-2024)

12 Supply Chain and Sales Channel Analysis

12.1 Neuromyelitis Optica Drug Supply Chain Analysis

12.2 Neuromyelitis Optica Drug Key Raw Materials and Upstream Suppliers

12.3 Neuromyelitis Optica Drug Clients Analysis

12.4 Neuromyelitis Optica Drug Sales Channel and Sales Model Analysis

12.4.1 Neuromyelitis Optica Drug Distribution Channel Analysis: Indirect Sales VS Direct Sales

12.4.2 Neuromyelitis Optica Drug Distribution Channel Analysis: Online Sales VS Offline Sales

12.4.3 Neuromyelitis Optica Drug Distributors

13 Market Dynamics

13.1 Neuromyelitis Optica Drug Industry Trends

13.2 Neuromyelitis Optica Drug Market Drivers

13.3 Neuromyelitis Optica Drug Market Challenges

13.4 Neuromyelitis Optica Drug Market Restraints

14 Research Findings and Conclusion

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Major Companies of Glucocorticoids

Table 3. Major Companies of Immunotherapies

Table 4. Major Companies of Others

Table 5. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million): 2023 VS 2030

Table 7. Global Neuromyelitis Optica Drug Revenue by Region (2019-2024) & (US$ Million)

Table 8. Global Neuromyelitis Optica Drug Revenue Forecast by Region (2025-2030) & (US$ Million)

Table 9. Neuromyelitis Optica Drug Revenue by Company (2019-2024) & (US$ Million)

Table 10. Neuromyelitis Optica Drug Revenue Share by Company (2019-2024)

Table 11. Ranking of Global Top Neuromyelitis Optica Drug Players by Revenue (US$ Million) in 2023

Table 12. Global Neuromyelitis Optica Drug Companies Market Concentration Ratio (CR5 and HHI) & (2019-2024)

Table 13. Global Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2023)

Table 14. Global Neuromyelitis Optica Drug Companies Headquarters

Table 15. Global Neuromyelitis Optica Drug Companies Product & Service

Table 16. Date of International Companies Enter into Neuromyelitis Optica Drug Market

Table 17. Global Neuromyelitis Optica Drug Mergers & Acquisitions, Expansion Plans

Table 18. Pfizer Company Information

Table 19. Pfizer Description and Business Overview

Table 20. Pfizer Neuromyelitis Optica Drug Product

Table 21. Pfizer Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 22. Pfizer Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 23. Pfizer Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 24. Pfizer Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 25. Pfizer Recent Development

Table 26. Fresenius Company Information

Table 27. Fresenius Description and Business Overview

Table 28. Fresenius Neuromyelitis Optica Drug Product

Table 29. Fresenius Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 30. Fresenius Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 31. Fresenius Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 32. Fresenius Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 33. Fresenius Recent Development

Table 34. Teva Company Information

Table 35. Teva Description and Business Overview

Table 36. Teva Neuromyelitis Optica Drug Product

Table 37. Teva Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 38. Teva Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 39. Teva Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 40. Teva Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 41. Teva Recent Development

Table 42. Sandoz Company Information

Table 43. Sandoz Description and Business Overview

Table 44. Sandoz Neuromyelitis Optica Drug Product

Table 45. Sandoz Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 46. Sandoz Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 47. Sandoz Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 48. Sandoz Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 49. Sandoz Recent Development

Table 50. Intas Company Information

Table 51. Intas Description and Business Overview

Table 52. Intas Neuromyelitis Optica Drug Product

Table 53. Intas Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 54. Intas Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 55. Intas Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 56. Intas Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 57. Intas Recent Development

Table 58. Gyjtrs Company Information

Table 59. Gyjtrs Description and Business Overview

Table 60. Gyjtrs Neuromyelitis Optica Drug Product

Table 61. Gyjtrs Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 62. Gyjtrs Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 63. Gyjtrs Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 64. Gyjtrs Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 65. Gyjtrs Recent Development

Table 66. NANG KUANG Company Information

Table 67. NANG KUANG Description and Business Overview

Table 68. NANG KUANG Neuromyelitis Optica Drug Product

Table 69. NANG KUANG Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 70. NANG KUANG Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 71. NANG KUANG Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 72. NANG KUANG Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 73. NANG KUANG Recent Development

Table 74. Tianjin Kingyork Company Information

Table 75. Tianjin Kingyork Description and Business Overview

Table 76. Tianjin Kingyork Neuromyelitis Optica Drug Product

Table 77. Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 78. Tianjin Kingyork Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 79. Tianjin Kingyork Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 80. Tianjin Kingyork Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 81. Tianjin Kingyork Recent Development

Table 82. Baxter Company Information

Table 83. Baxter Description and Business Overview

Table 84. Baxter Neuromyelitis Optica Drug Product

Table 85. Baxter Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 86. Baxter Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 87. Baxter Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 88. Baxter Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 89. Baxter Recent Development

Table 90. CSL Company Information

Table 91. CSL Description and Business Overview

Table 92. CSL Neuromyelitis Optica Drug Product

Table 93. CSL Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 94. CSL Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 95. CSL Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 96. CSL Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 97. CSL Recent Development

Table 98. Grifols Company Information

Table 99. Grifols Description and Business Overview

Table 100. Grifols Neuromyelitis Optica Drug Product

Table 101. Grifols Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 102. Grifols Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 103. Grifols Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 104. Grifols Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 105. Grifols Recent Development

Table 106. Octapharma Company Information

Table 107. Octapharma Description and Business Overview

Table 108. Octapharma Neuromyelitis Optica Drug Product

Table 109. Octapharma Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 110. Octapharma Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 111. Octapharma Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 112. Octapharma Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 113. Octapharma Recent Development

Table 114. CBOP Company Information

Table 115. CBOP Description and Business Overview

Table 116. CBOP Neuromyelitis Optica Drug Product

Table 117. CBOP Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2019-2024)

Table 118. CBOP Revenue Proportion of Neuromyelitis Optica Drug by Product in 2023

Table 119. CBOP Revenue Proportion of Neuromyelitis Optica Drug by Application in 2023

Table 120. CBOP Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2023

Table 121. CBOP Recent Development

Table 122. Global Neuromyelitis Optica Drug Revenue by Type (2019-2024) & (US$ Million)

Table 123. Global Neuromyelitis Optica Drug Revenue Forecast by Type (2025-2030) & (US$ Million)

Table 124. Global Neuromyelitis Optica Drug Revenue by Application (2019-2024) & (US$ Million)

Table 125. Global Neuromyelitis Optica Drug Revenue Forecast by Application (2025-2030) & (US$ Million)

Table 126. North America Neuromyelitis Optica Drug Revenue by Country (2019-2024) & (US$ Million)

Table 127. North America Neuromyelitis Optica Drug Revenue by Country (2025-2030) & (US$ Million)

Table 128. North America Neuromyelitis Optica Drug Revenue by Type (2019-2024) & (US$ Million)

Table 129. North America Neuromyelitis Optica Drug Revenue by Application (2019-2024) & (US$ Million)

Table 130. Asia-Pacific Neuromyelitis Optica Drug Revenue by Region (2019-2030) & (US$ Million)

Table 131. Asia-Pacific Neuromyelitis Optica Drug Revenue by Region (2025-2030) & (US$ Million)

Table 132. Asia-Pacific Neuromyelitis Optica Drug Revenue by Type (2019-2024) & (US$ Million)

Table 133. Asia-Pacific Neuromyelitis Optica Drug Revenue by Application (2019-2024) & (US$ Million)

Table 134. Europe Neuromyelitis Optica Drug Revenue by Country (2019-2024) & (US$ Million)

Table 135. Europe Neuromyelitis Optica Drug Revenue by Country (2025-2030) & (US$ Million)

Table 136. Europe Neuromyelitis Optica Drug Revenue by Type (2019-2024) & (US$ Million)

Table 137. Europe Neuromyelitis Optica Drug Revenue by Application (2019-2024) & (US$ Million)

Table 138. Latin America Neuromyelitis Optica Drug Revenue by Country (2019-2024) & (US$ Million)

Table 139. Latin America Neuromyelitis Optica Drug Revenue by Country (2025-2030) & (US$ Million)

Table 140. Latin America Neuromyelitis Optica Drug Revenue by Type (2019-2024) & (US$ Million)

Table 141. Latin America Neuromyelitis Optica Drug Revenue by Application (2019-2024) & (US$ Million)

Table 142. Middle East and Africa Neuromyelitis Optica Drug Revenue by Country (2019-2024) & (US$ Million)

Table 143. Middle East and Africa Neuromyelitis Optica Drug Revenue by Country (2025-2030) & (US$ Million)

Table 144. Middle East and Africa Neuromyelitis Optica Drug Revenue by Type (2019-2024) & (US$ Million)

Table 145. Middle East and Africa Neuromyelitis Optica Drug Revenue by Application (2019-2024) & (US$ Million)

Table 146. Neuromyelitis Optica Drug Key Raw Materials, Industry Status and Trend

Table 147. Neuromyelitis Optica Drug Key Raw Materials and Upstream Suppliers

Table 148. Neuromyelitis Optica Drug Clients Status and Trend

Table 149. Neuromyelitis Optica Drug Typical Clients

Table 150. Neuromyelitis Optica Drug Distributors

Table 151. Neuromyelitis Optica Drug Market Trends

Table 152. Neuromyelitis Optica Drug Market Drivers

Table 153. Neuromyelitis Optica Drug Market Challenges

Table 154. Neuromyelitis Optica Drug Market Restraints

Table 155. Research Programs/Design for This Report

Table 156. Key Data Information from Secondary Sources

Table 157. Key Data Information from Primary Sources

List of Figures

Figure 1. Neuromyelitis Optica Drug Product Picture

Figure 2. Global Neuromyelitis Optica Drug Revenue Market Share by Type in 2023 & 2030

Figure 3. Glucocorticoids Product Picture

Figure 4. Immunotherapies Product Picture

Figure 5. Others Product Picture

Figure 6. Global Neuromyelitis Optica Drug Revenue Market Share by Application in 2023 & 2030

Figure 7. Acute Attack

Figure 8. Remission Prophylactic Treatment

Figure 9. Neuromyelitis Optica Drug Report Years Considered

Figure 10. Global Neuromyelitis Optica Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 11. Global Neuromyelitis Optica Drug Market Size 2019-2030 (US$ Million)

Figure 12. Global Neuromyelitis Optica Drug Market Size Market Share by Region: 2023 Versus 2030

Figure 13. Global Neuromyelitis Optica Drug Revenue Market Share by Region (2019-2030)

Figure 14. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 15. Global Neuromyelitis Optica Drug Revenue Market Share Forecast by Type (2019-2030)

Figure 16. Global Neuromyelitis Optica Drug Revenue Market Share Forecast by Application (2019-2030)

Figure 17. North America Neuromyelitis Optica Drug Revenue 2019-2030 (US$ Million)

Figure 18. North America Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2024)

Figure 19. North America Neuromyelitis Optica Drug Revenue Market Share by Application (2019-2024)

Figure 20. Asia-Pacific Neuromyelitis Optica Drug Revenue 2019-2030 (US$ Million)

Figure 21. Asia-Pacific Neuromyelitis Optica Drug Revenue Market Share by Region (2019-2030)

Figure 22. Asia-Pacific Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2024)

Figure 23. Asia-Pacific Neuromyelitis Optica Drug Revenue Market Share by Application (2019-2024)

Figure 24. Europe Neuromyelitis Optica Drug Revenue Growth Rate 2019-2030 (US$ Million)

Figure 25. Europe Neuromyelitis Optica Drug Revenue Market Share by Country (2019-2030)

Figure 26. Europe Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2024)

Figure 27. Europe Neuromyelitis Optica Drug Revenue Market Share by Application (2019-2024)

Figure 28. Latin America Neuromyelitis Optica Drug Revenue Growth Rate 2019-2030 (US$ Million)

Figure 29. Latin America Neuromyelitis Optica Drug Revenue Market Share by Country (2019-2024)

Figure 30. Latin America Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2024)

Figure 31. Latin America Neuromyelitis Optica Drug Revenue Market Share by Application (2019-2024)

Figure 32. Middle East and Africa Neuromyelitis Optica Drug Revenue Growth Rate 2019-2030 (US$ Million)

Figure 33. Middle East and Africa Neuromyelitis Optica Drug Revenue Market Share by Country (2019-2030)

Figure 34. Middle East and Africa Neuromyelitis Optica Drug Revenue Market Share by Type (2019-2024)

Figure 35. Middle East and Africa Neuromyelitis Optica Drug Revenue Market Share by Application (2019-2024)

Figure 36. Neuromyelitis Optica Drug Supply Chain (Upstream and Downstream Market)

Figure 37. Global Production Market Share of Neuromyelitis Optica Drug Raw Materials by Region in 2023

Figure 38. Neuromyelitis Optica Drug Distribution Channels

Figure 39. Global Neuromyelitis Optica Drug Percentage 2019-2030: Indirect Sales VS Direct Sales

Figure 40. Global Neuromyelitis Optica Drug Percentage 2019-2030: Online Sales VS Offline Sales

Figure 41. Bottom-up and Top-down Approaches for This Report

Figure 42. Data Triangulation

Figure 43. Key Executives Interviewed

Figure 44. Global Neuromyelitis Optica Drug Percentage 2019-2030: Online Sales VS Offline Sales

Figure 45. Bottom-up and Top-down Approaches for This Report

Figure 46. Data Triangulation

Figure 47. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$5900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions